Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-04-23 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of 康芝药业股份有限公司, indicating it is a summary of the full annual report. It contains detailed company information, business overview, industry analysis, financial data for the year 2022, and shareholder information. The presence of comprehensive financial figures, business descriptions, and strategic outlook aligns with the characteristics of an Annual Report (10-K). The document is over 12,000 characters, indicating it is substantive and not merely an announcement or a brief summary. There is no indication that this is a certification, proxy statement, or a regulatory filing of another type. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-04-23 Chinese
关于预计2023年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the fiscal year 2023 by 康芝药业股份有限公司. It details the nature, amounts, and approval process of these transactions, including board meeting resolutions and independent director opinions. The document is a formal announcement of planned related party transactions, not a financial report or audit. It does not contain financial statements or detailed financial analysis but rather disclosures and approvals related to corporate governance and compliance with regulations on related party transactions. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about related party transactions and board approvals, not a full report or financial statement.
2023-04-23 Chinese
2022年年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised by the company 康芝药业股份有限公司 for the year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The content includes specifics on the amount raised, usage, balances, investment projects, changes in investment projects, and compliance with disclosure requirements. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2022. This type of report is a specialized disclosure related to capital raised and its management, which aligns with the category of Capital/Financing Update (CAP). It is not a general annual report, earnings release, or other types of filings. The length and detail confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-23 Chinese
公司2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a "2022年度财务决算报告" which translates to "2022 Annual Financial Settlement Report". It contains detailed financial statements including balance sheet, income statement, cash flow statement, and notes, audited by an accounting firm with an audit opinion included. The document provides comprehensive financial data for the full fiscal year 2022, including assets, liabilities, equity, revenues, profits, and various financial ratios. The presence of audited financial statements and full-year financial results indicates this is a full annual report rather than a short announcement or a partial report. The document length is 2579 characters, which is relatively short, but the content includes substantive financial data and analysis, not just a notice or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-23 Chinese
2022年度独立董事述职报告 张继承
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 by an independent director of the company. It details the director's attendance at board meetings, opinions on various company matters, committee work, on-site inspections, investor protection efforts, training, and other work activities. The content is a narrative report on the director's duties and activities during the year rather than a financial report or regulatory filing. It does not contain financial statements, audit opinions, or earnings data. It is not an announcement or a proxy solicitation. This type of document is best classified under Board/Management Information (MANG) as it relates to board member activities and governance roles.
2023-04-23 Chinese
关于康芝药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" which translates to a "special audit report" related to non-operating fund occupation and other related party fund transactions for Kangzhi Pharmaceutical Co., Ltd. It is issued by a certified public accounting firm and is intended for use in the 2022 annual report disclosure. The document contains audit findings and financial figures for the year 2022. The length is 2335 characters, which is relatively short but contains substantive audit content rather than just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) because it is a specific audit report, not a full yearly report. It is not a Regulatory Filing (RNS) because it contains actual audit content, not just a certification or announcement. Therefore, the correct classification is AR with high confidence. FY 2022
2023-04-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.